Program
selexipag
Also written as “Selexipag”, “selexipag (Uptravi)” and “Selexipag Film Coated Tablets (T1)”.
Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Hypertension · Scleroderma, Systemic · Sarcoidosis, led by 2 companies.
Drug pageSelexipag: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 213 open or running | phase 4since Mar 6, 2017 | Apr 2, 2010 | Jan 31, 2027phase 3 · NCT05179876 |
| Humanis Saglık Anonim Sirketi | 20 open or running | phase 1since Apr 10, 2025 | Apr 10, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Humanis Saglık Anonim Sirketi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 10, 2025First study: phase 1 study in Pulmonary Arterial HypertensionFirst studyNCT06932198 · 14 enrolled · Jordan
- Jul 3, 2026Phase 1 study in HypertensionNCT07694128 · 30 enrolled · India
TargetBeta
“Prostanoid IP receptor agonist”ChEMBL 37, by rule
Other programs on PTGIR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| treprostinilrule | United Therapeutics | phase 4 | 73 |
Studies
All 2 Humanis Saglık Anonim Sirketi leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07694128Hypertension · India | 1 | Completed | Jun 16, 2026 | 30 |
| NCT06932198Pulmonary Arterial Hypertension · Jordan | 1 | Completed | Mar 3, 2025 | 14 |
How it is read
Names in the registry
- “Selexipag”, 13 entries
- “selexipag”, 2 entries
- “selexipag (Uptravi)”, 1 entry
- “Selexipag Film Coated Tablets (T1)”, 1 entry
- “Selexipag Film Coated Tablets (T2)”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 9 studies
- Hypertension, Pulmonary, 4 studies
- Hypertension, 1 study
- Scleroderma, Systemic, 1 study
- Sarcoidosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.